Fisher & Paykel launches new sleep apnoea device, while ResMed touts double-digit growth

MedTech & Diagnostics News: Fisher & Paykel Healthcare unveiled its latest innovation, touted as the “smallest and lightest” device for treating obstructive sleep apnoea (OSA). Meanwhile, ResMed announced robust double-digit revenue growth in OSA mask and accessories sales.

The Fisher & Paykel (F&P) Nova Micro nasal pillows mask weighs a mere 40 grams, boasting minimal, easy-adjusting headgear and a MicroPillows cushion that conforms snugly to the nostrils. Engineered for stability and flexibility, it allows patients to sleep in their preferred positions without compromise.

“Nova Micro was created for patients wanting a mask that doesn’t compromise on comfort and performance,” said Andrew Somervell, VP Products and Technology. “‘Less is best’ was the mantra for our teams throughout the development process, and the result is our smallest and lightest mask yet.”

Highlighting the expansion of their mask portfolio, Somervell added, “With this new nasal pillows option, along with our recently released F&P Solo AutoFit mask and the F&P Evora Full, we will be able to cater to a wide range of patient needs and preferences.”

Initial sales of the Nova Micro have commenced in New Zealand and United States, with plans for a rollout in Canada in the coming months, followed by launches in Australia and Europe later this year. The headgear comes in one size, complemented by three MicroPillows cushion sizes.

Backed by positive internal validation trial results, 97% of users rated the cushion feel as ‘soft’ or ‘very soft’, and 100% praised the overall performance as ‘good’ or ‘very good’. Moreover, 95% of users reported being able to set up the mask without assistance, and 93% of patients rated their experience with the mask as ‘simple’ or ‘very simple’.

In parallel, ResMed revealed robust double-digit revenue growth in OSA mask and accessories sales for the third-quarter fiscal year 2024.

Coinciding with World Sleep Day in March, ResMed released findings from its 4th annual Global Sleep Survey of 36,000 individuals across 17 markets.

The survey highlighted that 50% of respondents reported experiencing excessive daytime sleepiness, while 40% reported getting no more than three nights of good sleep per week. Moreover, more than one-third of respondents are actively monitoring their sleep patterns, utilising smartphone apps (44%) or wearable devices (31%).

“We remain laser-focused on bringing market-leading innovation to customers, including our latest AirCurve11 range of non-invasive ventilators and our recently launched AirFit F40 mask system, combined with our entire portfolio of products, software, and solutions, allowing us to continue to deliver value for all our stakeholders,” said ResMed CEO and Chairman Mick Farrell.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.